Verastem Inc (FRA:2VSA)
€ 3.7 -0.34 (-8.42%) Market Cap: 158.44 Mil Enterprise Value: 109.90 Mil PE Ratio: 0 PB Ratio: 13.49 GF Score: 32/100

Verastem Inc at RBC Capital Markets Global Healthcare Conference Transcript

May 17, 2023 / 06:05PM GMT
Release Date Price: €3.89 (+1.57%)
Greg Renza
RBC Capital Markets - Analyst

Welcome back, everyone, to the 2023 RBC Global Healthcare Conference. My name is Greg Renza, one of the senior biotech equity research analysts here at RBC. And we're pleased to be joined for this session by Verastem.

Joining us from the company is the Chief Executive Officer, Brian Stuglik; and the Chief Scientific Officer, Jon Pachter. So it's great to have you guys.

Questions & Answers

Greg Renza
RBC Capital Markets - Analyst

Brian, I think I just wanted to just start by having you give us a brief overview of Verastem -- a great deal going on. Many folks are familiar with the name of the company, but there are some interesting developments with your lead asset. And I think bringing investors up to speed is worthwhile.

Brian Stuglik
Verastem, Inc. - CEO

Yeah, sure. Great. Thanks, Greg. So several years ago, we pivoted the company. We started with the product -- our company was founded on a product called defactinib back in 2012. And again, we did some

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot